Skip to main content
SpringerLink
Log in

Intraperitoneal Biologic Therapy for Ovarian Cancer

  • Chapter
Regional Chemotherapy

Part of the book series: Current Clinical Oncology ((CCO))

  • 100 Accesses

Abstract

Epithelial ovarian carcinoma (EOC) is the leading cause of death from gynecologic malignancies in the United States, and is the fourth most common cause of cancer death in women. It is estimated that one in 70 women will develop ovarian cancer (OC) in her lifetime, and one in 100 will die of this disease. Although OC is sensitive to a variety of chemotherapeutic agents, the 5-yr survival for advanced disease remains only about 20%. Because of the poor long-term survival for advanced OC, investigators have sought to develop novel biologic therapies to combat this disease. Biologic therapies produce antitumor effects through the activation of the host’ s natural defense mechanisms. This may be particularly important in advanced OC, in which patients have been shown to be significantly immunocompromised (1). Unfortunately, the initial trials of systemic biologic agents failed to elicit consistent responses in patients with OC.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Khoo SK and Mackay EV. Immunologic reactivity of female patients with genital cancer: status in preinvasive, locally invasive and disseminated disease, Am. J. Obstet. Gynecol., 119 (1974) 1018–1025.

    PubMed  CAS  Google Scholar 

  2. Markman M and Howell SB. Intraperitoneal chemotherapy for ovarian cancer, In Alberts DS, Surwit EA (eds), Ovarian Cancer. Martinus Nijhoff, Boston, 1985, pp. 179–212.

    Chapter  Google Scholar 

  3. Clark JW. Biological response modifiers. Cancer Chemother. Biol. Response Modif. 17 (1997) 287–315.

    PubMed  CAS  Google Scholar 

  4. Benjamini E, Rennick DM, and Sell S. Tumor immunology, In Stites DP, et al. (eds), Basic and Clinical Immunology, Lange, Los Altos, CA, 1984, 223.

    Google Scholar 

  5. Boyer P, Berek JS, and Zigelboim J. Lymphocyte activation by recombinant interleukin-2 in ovarian cancer patients, Obstet. Gynecol., 73 (1989) 793–797.

    PubMed  CAS  Google Scholar 

  6. Marx JL. T-cell receptor—the genes and beyond, Science, 227 (1985) 733–755.

    Article  PubMed  CAS  Google Scholar 

  7. Hedrick SM, Cohen DI, Nielsen EA, and Davis MM. Isolation of cDNA clones encoding T-cellspecific membrane-associated proteins, Nature, 308 (1984) 149–153.

    Article  PubMed  CAS  Google Scholar 

  8. Williams AF. T-lymphocyte receptor—elusive no more, Nature, 308 (1984) 108–109.

    Article  PubMed  CAS  Google Scholar 

  9. Kotzin BL, Benike CJ, and Engleman EG. Induction of immunoglobulin secreting cells in the allogenic mixed leukocyte reaction: regulation by helper and suppressor lymphocyte subsets in man, J. Immunol., 127 (1981) 931–935.

    PubMed  CAS  Google Scholar 

  10. Berke G. Functions and mechanisms of lysis induced by cytotoxic lymphocytes and natural killer cells, In Paul’s Fundamental Immunology, Raven, New York, 1989, pp. 735–764.

    Google Scholar 

  11. Herberman RB. Natural Cell-Mediated Immunity Against Tumors, Academic, New York, 1980, 973.

    Google Scholar 

  12. Lanzavecchia A. Antigen-specific interaction between T and B cells, Nature, 314 (1985) 537–539.

    Article  PubMed  CAS  Google Scholar 

  13. Unanue ER and Allen PM. Basis for the immunoregulatory role of macrophages and other accessory cells, Science, 236 (1987) 551–557.

    Article  PubMed  CAS  Google Scholar 

  14. Grimm EA, Mazumder A, Zhang HZ, and Rosenberg SA. Lymphokine activated killer cell phenomenon: lysis of NK resistant fresh solid tumor cells by IL-2 activated autologous human peripheral blood lymphocytes, J. Exp. Med.,155 (1982) 1823–1841.

    Article  PubMed  CAS  Google Scholar 

  15. Halpern B. Corynebacterium parvum: application in experimental and clinical oncology, Plenum, New York, 1975.

    Book  Google Scholar 

  16. Chen MF, Suzuki H, and Yano S. Induction of murine lymphokine-activated killer-like cells by Corynebacterium parvum (C. parvum) in vitro: Lysis of tumor cells and macrophages by C. parvuminduced killer cells. Anticancer Res., 12 (1992) 451–456.

    PubMed  CAS  Google Scholar 

  17. Berek JS, Knapp RC, Hacker NF, et al. Intraperitoneal immunotherapy of epithelial ovarian cancer with Corynebacterium parvum, Am. J. Obstet. Gynecol., 152 (1985) 1003–1010.

    PubMed  CAS  Google Scholar 

  18. Bast RC, Berek JS, Obrist R, et al. Intraperitoneal immunotherapy of human ovarian carcinoma with Cornyebacterium parvum, Cancer Res., 43 (1983) 1395–1401.

    PubMed  Google Scholar 

  19. Mantovani A. Intraperitoneal administration of Corynebacterium parvum by chemical fractionation, Int. J. Immunopharmacol., 2 (1981) 437–446.

    Google Scholar 

  20. Lichtenstein A, Berek JS, Bast RC, et al. Activation of peritoneal lymphocyte cytotoxicity in patients with ovarian cancer by intraperitoneal treatment with Corynebacterium parvum, J. Biol. Response Mod., 3 (1984) 371–378.

    PubMed  CAS  Google Scholar 

  21. Ohkawa K and Ohkawa R. Locoregional immunotherapy and chemotherapy in advanced ovarian cancer cytotoxicity, Asian Oceania Fed. Obstet. Gynecol., (October 1981) 352.

    Google Scholar 

  22. Kawagoe K and Masuda J. Advanced ovarian cancer treated by intraperitoneal immunotherapy with OK-432, Jpn. J. Clin. Oncol., 16 (1986) 137–142.

    PubMed  CAS  Google Scholar 

  23. Koelbl H, Micksche M, Gitsch G, Hanzal E, and Nowotny C. Treatment with biologic response modifiers in patients with ovarian cancer, Eur. J. Obstet. Gynecol. Reprod. Biol., 41 (1991) 64–69.

    Article  PubMed  CAS  Google Scholar 

  24. Zighelboim J, Niio Y, Berek JS, and Bonavida B. Immunologic control of ovarian cancer, Nar. Immunol. Cell Growth Regul., 7 (1988) 216–225.

    CAS  Google Scholar 

  25. Philip R. Cytolysis of tumor necrosis factor (TNF)-resistant tumor targets. Differential cytotoxicity of monocytes activated by the interferons, IL-2, and TNF. J. Immunol. 140 (1988) 1345–1349.

    PubMed  CAS  Google Scholar 

  26. Berek JS, Cantrell JL, Lichtenstein AK, et al. Immunotherapy with biochemically dissociated fractions of proprionebacterium acnes in a murine ovarian cancer model, Cancer Res., 44 (1984) 1871–1875.

    PubMed  CAS  Google Scholar 

  27. Niloff TM, Knapp RC, Jones G, et al. Recombinant leukocyte alpha interferon in advanced ovarian carcinoma, Cancer Treat. Rep., 69 (1985) 895–896.

    PubMed  CAS  Google Scholar 

  28. Berek JS, Hacker NF, Lichtenstein AK, et al. Intraperitoneal recombinant alpha-interferon for salvage immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Study group, Cancer Res., 45 (1985) 4447–4453.

    PubMed  CAS  Google Scholar 

  29. Moore DH, Valea F, Walton LA, Soper J, Clarke-Pearson D, and Fowler WC Jr. Phase I study of intraperitoneal interferon-alpha 2b and intravenous cis-platinum plus cyclophospamide chemotherapy in patients with untreated stage III epithelial ovarian cancer: a gynecologic Ongolocy Group pilot study, Gynecol. Oncol., 59 (1995) 267–272.

    Article  PubMed  CAS  Google Scholar 

  30. Willemse PH, De Bries EGE, Aalers JG, et al. Intraperitoneal human recombinant interferon alpha-2b in minimal residual ovarian cancer, Eur. J. Cancer, 26 (1990) 353–358.

    Article  PubMed  CAS  Google Scholar 

  31. Aapro MS, Alberts DS, and Salmon SE. Interaction of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay, Cancer Chemother. Pharmacol., 10 (1983) 161–166.

    Article  PubMed  CAS  Google Scholar 

  32. Berek JS, Welander C, Schink JC, Grossberg H, Montz FJ, and Zigelboim J. Phase I-II trial of intraperitoneal cisplatin and alpha-interferon in patients with persistent epithelial ovarian cancer, Gynecol. Oncol., 40 (1991) 237–243.

    Article  PubMed  CAS  Google Scholar 

  33. Nardi M, Cognetti F, Pollera CF, et al. Intraperitoneal recombinant alpha-2-interferon alternating with cisplatin as salvage therapy for minimal residual disease ovarian cancer. A phase II study, J. Clin. Oncol., 8 (1990) 1036–1041.

    PubMed  CAS  Google Scholar 

  34. Stuart GC, Nation JG, Snider DD, and Thunberg P. Intraperitoneal interferon in the management of malignant ascites, Cancer, 27 (1993) 1423–1429.

    Google Scholar 

  35. Meanpaa J, Kivinen S, Raisanen I, Sipiila P, Vayrynen M, and Grohn P. Combined intraperitoneal interferon alpha-2b and mitoxantrone in refractory ovarian cancer, Ann. Chir. Gynaecol., 208 (suppl) (1994) 25–27.

    Google Scholar 

  36. Bezwoda WR, Golombick T, Dansey R, and Keeping J. Treatment of malignant ascites due to recurrent/ refractory ovarian cancer: the use of interferon-alpha or interferon-alpha plus chemotherapy in vivo and in vitro, Eur. J. Cancer, 27 (1991) 1423–1429.

    Article  PubMed  CAS  Google Scholar 

  37. Frasci G, Tortoriello A, Facchini G, et al. Carboplatin and alpha-2b interferon intraperitoneal combination as first-line treatment of minimal residual ovarian cancer. A pilot study, Curr. J. Cancer, 30A (1994) 946–950.

    Google Scholar 

  38. Moore DH, Valea F, Walton LA, Soper J, Clarke-Pearson D, and Fowler WC Jr. Phase I study of intraperitoneal interferon-alpha 2b and intravenous cis-platinum plus cyclophospamide chemotherapy in patients with untreated stage III epithelial ovarian cancer: a gynecologic Oncology Group pilot study, Gynecol. Oncol., 59 (Nov. 1995) 267–272.

    Article  PubMed  CAS  Google Scholar 

  39. Bruzzone M, Rubagotti A, Gadducci A, et al. Intraperitoneal carboplatin with or without interferon-alpha in advanced ovarian cancer patients with minimal residual disease at second look: a prospective randomized trial of 111 patients, Gruppo Oncologic Nord Ovest, Gynecol. Oncol., 65 (1997) 499–505.

    Article  PubMed  CAS  Google Scholar 

  40. Golub SH. Immunological and therapeutic effects of interferon treatment of cancer patients, Clin. Immunol. Allergy, 4 (1984) 377.

    Google Scholar 

  41. D’Acquisto R, Markman M, Hakes, et al. Phase I trial of intraperitoneal recombinant gamma-interferon in advanced ovarian carcinoma, J. Clin. Oncol., 6 (1988) 689–695.

    PubMed  Google Scholar 

  42. Marth C, Mull R, Gastl G, et al. Intraperitoneal installation of gamma interferon for the treatment of refractory ovarian carcinoma, Geburtshilfe Frauenheilkd 49 (1989) 987–991.

    Article  PubMed  CAS  Google Scholar 

  43. Pujade-Lauraine E, Colombo N, Maner N, et al. Intraperitoneal human r-interferon gamma in patients with residual ovarian carcinoma at second look laparotomy, Proc. Am. Soc. Clin. Oncol., 9 (1990) 156.

    Google Scholar 

  44. Pujade-Lauraine E, Guastalla JP, Colombo N. et al. Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy, J. Clin. Oncol.,14 (1996) 343–350.

    PubMed  CAS  Google Scholar 

  45. Old LJ. Tumor necrosis factor, Science, 230 (1985) 630 - 632.

    Article  PubMed  CAS  Google Scholar 

  46. Chapman PB, Lester TS, Casper ES, et al. Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer, J. Clin. Oncol., 5 (1987) 1942–1951.

    PubMed  CAS  Google Scholar 

  47. Spriggs DR, Sherman ML, and Michie H. Recombinant human tumor necrosis factor administered as a 24-hr intravenous infusion. A phase I and pharmacologic study, J. Natl. Cancer Inst., 80 (1988) 1039–1044.

    Article  PubMed  CAS  Google Scholar 

  48. Markman M, Lanotti N, Hakes T, et al. Phase I trial of intraperitoneal recombinant tumor necrosis factor, Proc. Am. Soc. Clin. Oncol., 8 (1989) 64.

    Google Scholar 

  49. Kaufmann M, Schmid H, Raeth U, et al. Therapy of ascites with tumor necrosis factor in ovarian cancer, Geburtshilfe Frauenheilkd, 9 (1990) 678–682.

    Article  Google Scholar 

  50. Rath U, Kaufmann M, Schmid H, et al. Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites, Eur. J. Cancer, 27 (1991) 121–125.

    Article  PubMed  CAS  Google Scholar 

  51. Hirte HW, Miller D, Tonkin K, et al. Randomized trial of paracentesis plus intraperitoneal tumor necrosis factor-alpha paracentesis alone in patients with symptomatic ascites from recurrent ovarian carcinoma, Gynecol. Oncol., 64 (1997) 80–87.

    Article  PubMed  CAS  Google Scholar 

  52. Bonavida B, Tsuchitani T, Zighelboim J, and Berek JS. Synergy is documented in vitro with low dose tumor necrosis factor, cisplatin, and doxorubicin in ovarian cells, Gynecol. Oncol., 38 (1990) 333–339.

    Article  PubMed  CAS  Google Scholar 

  53. Edwards RP, Gooding W, Lembersky BC, et al. Recombinant interleukin-2 continuous infusion in ovarian cancer patients with minimal residual disease at second-look, Cancer Treat. Rev., 16 (1989) 123 - 127.

    Article  Google Scholar 

  54. Urba WJ, Clark JW, Steis RG, et al. Intraperitoneal lymphokine-activated killer cell/interleukin-2 therapy in patients with intra-abdominal cancer: immunologic considerations, J. Natl. Cancer Inst., 19 (1989) 602–611.

    Article  Google Scholar 

  55. Steis RG, Urba WJ, Van der Molen LA, et al. Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity, J. Clin. Oncol.,10 (1990) 1618–1629.

    Google Scholar 

  56. Edwards RP, Gooding W, Lembersky BC, Colonello K, Hammond R, Paradise C, et al. Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion, J. Clin. Oncol., 15 (1997) 3399–3407.

    PubMed  CAS  Google Scholar 

  57. Beller U, Abraham C, James L, et al. Phase IB study of low-dose intraperitoneal recombinant interleukin-2 in patients with refractory advanced ovarian cancer: rational and preliminary report, Gynecol. Oncol.,34 (1989) 407–412.

    Article  Google Scholar 

  58. Chapman PB, Kolitz JE, Hakes TB, et al. Phase I trial of intraperitoneal recombinant interleukin-2 in patients with ovarian carcinoma, Invest. New Drugs, 3 (1988) 179–188.

    Google Scholar 

  59. Panici PB, Scambia G, Greggi S, et al. Recombinant interleukin-2 continuous infusion in ovarian cancer patients with minimal residual disease at second-look, Cancer Treat. Rev., 16 (1989) 123–127.

    Article  Google Scholar 

  60. Stewart JA, Belinson JL, Moore AL, et al. Phase I trial of intraperitoneal recombinant interleukin-2/ lymphokine-activated killer cells in patients with ovarian cancer, Cancer Res.,50 (1990) 6302–6310.

    Google Scholar 

  61. Valone FH, Kaufman PA, Guyre PM, et al. Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2/neu, J. Hematother.,4 (1995) 471–475.

    Article  PubMed  CAS  Google Scholar 

  62. Lucci JA, Manetta A, Cappuccini F, et al Immunotherapy of ovarian cancer. II. In vitro generation and characterization of lymphokine-activated killer T cells from the peripheral blood of recurrent ovarian cancer patients, Gynecol. Oncol.,45 (1992) 129–135.

    Article  PubMed  Google Scholar 

  63. Hwu P and Rosenberg SA. Genetic modification of T cells for cancer therapy: an overview of laboratory and clinical trials, Cancer Detect. Prey., 18 (1994) 43–50.

    CAS  Google Scholar 

  64. Hwu P, Yang JC, Cowherd R, et al. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes, Cancer Res., 55 (1995) 3369–3373.

    PubMed  CAS  Google Scholar 

  65. Hwu P, Shafer GE, Treisman J, et al. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor g chain, J. Exp. Med., 178 (1993) 361–366.

    Article  PubMed  CAS  Google Scholar 

  66. Epenetos AA, Hooker G, and Krausz T. Antibody-guided irradiation of malignant ascites ovarian cancer: a new therapeutic method possessing specificity against cancer cells, Obstet. Gynecol., 68 (1986) 71s–74s.

    PubMed  CAS  Google Scholar 

  67. Stewart JS, Hird V, Snook D, et al. Intraperitoneal radioimmunotherapy for ovarian cancer: pharmacokinetics, toxicity and efficacy of 131 I labelled monoclonal antibodies, Int. J. Radiat. Oncol. Biol. Phys., 16 (1989) 405–413.

    Article  PubMed  CAS  Google Scholar 

  68. Ward B, Mather S, Shepaherd J, et al. Treatment of intraperitoneal malignant disease with monoclonal antibody guided 131I radiotherapy, Br. J. Cancer, 58 (1988) 658–662.

    Article  PubMed  CAS  Google Scholar 

  69. Finkler NJ, Muto MG, Kassis AI, et al. Intraperitoneal radiolabelled OC125 in patients with advanced ovarian cancer, Gynecol. Oncol., 34 (1989) 339–344.

    Article  PubMed  CAS  Google Scholar 

  70. Hnatowich DJ, Mardirossian G, and Rose PG. Intraperitoneal therapy of ovarian cancer with Yttrium90-labelled monoclonal antibodies: preliminary observations, Antibiot. Immunoconjug. Radiopharmacol., 4 (1991) 359–371.

    Google Scholar 

  71. Muto MG, Finkler NJ, Kassis AI, et al. Intraperitoneal radioimmunotherapy of refractory ovarian carcinoma utilizing iodine-131-labelled monoclonal antibody OC125, Gynecol. Oncol.,45 (1992) 265–272.

    Article  PubMed  CAS  Google Scholar 

  72. Alvarez RD, Partridge EE, Khazeli MB, et al. Intraperitoneal radioimmunotherapy of ovarian cancer with 177-Lu-CC49: a phase 1/1I study, Gynecol. Oncol., 65 (1997) 94–101.

    Article  PubMed  CAS  Google Scholar 

  73. Schmolling J, Wagner U, Reinsberg J, Biersack HJ, and Krebs D. Immune reactions and survival of patients with ovarian carcinomas after administration of 131I-F(Ab)2 fragments of the OC 125 monoclonal antibody, Geburtshilfe Frauenheilkd., 55 (1995) 200–203.

    Article  PubMed  CAS  Google Scholar 

  74. Madiyalakan R, Sykes TR, Dharampaul S, et al. Antiidiotype induction therapy: evidence for the induction of immune response through the idiotype network in patients with ovarian cancer after administration of anti-CAl25 murine monoclonal antibody B43.13, Hybridoma, 14 (1995) 199–203.

    Article  PubMed  CAS  Google Scholar 

  75. Wagner U, Reinsberg J, Schmidt S, et al. Monoclonal antibodies and idiotypic network activation for ovarian carcinoma, Cell Biophys., 24/25 (1994) 237–242.

    PubMed  Google Scholar 

  76. Sobol RE, Shawler DL, Dorigo O, Gold D, Royston I, and Fakhrai H Immunogene therapy of cancer, In Sobol RE, Scanlon KJ (eds), Internet Book of Gene Therapy, Appleton and Lange, Norwalk, 1995, pp. 175–180.

    Google Scholar 

  77. Vile R and Russell SJ. Gene transfer technologies for the gene therapy of cancer, Gene Ther., 1 (1995) 88–89.

    Google Scholar 

  78. Kriegler M. Gene Transfer and Expression. A Laboratory Manual. New York, Stockton, 1990.

    Google Scholar 

  79. Puyal C, Milhaud P, Bienvenue A, and Philippot JR. New cationic liposome encapsulating genetic material. A potential delivery system for polynucleotides, Eur. J. Biochem., 228 (1995) 697–703.

    Article  PubMed  CAS  Google Scholar 

  80. Hofland H and Huang L. Inhibition of human ovarian carcinoma cell proliferation by liposomeplasmid DNA complex, Biochem. Biophys. Res. Commun., 207 (1995) 492–496.

    Article  PubMed  CAS  Google Scholar 

  81. Jolly D. Viral vectors systems for gene therapy, Cancer Gene Ther., 1 (1994) 51–64.

    PubMed  CAS  Google Scholar 

  82. Miller AD. Retroviral vectors, Curr. Top. Microbiol. Immunol., 3 (1993) 102–109.

    Google Scholar 

  83. Welsh RM, Cooper NR, Jensen FC, and Oldstone MBA. Human serum lyses RNA tumour viruses, Nature, 257 (1975) 612–614.

    Article  PubMed  CAS  Google Scholar 

  84. Addison CL, Braciak T, Ralston R, et al. Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model, Proc. Natl. Acad. Sci. USA, 92 (1995) 8522–8526.

    Article  PubMed  CAS  Google Scholar 

  85. Miller AR, McBride WH, Hunt K, and Economou JS. Cytokine-mediated gene therapy for cancer, Ann. Surg. Oncol., 1 (1994) 436–450.

    Article  PubMed  CAS  Google Scholar 

  86. Dorigo O, Shawler DL, Royston I, Sobol RE, Berek JS, and Fakhrai H. Combination of transforming growth factor beta antisense and interleukin-2 gene therapy in the murine ovarian teratoma model Gynecol. Oncol., 71 (1998) 204–210.

    Article  PubMed  CAS  Google Scholar 

  87. Shawler DL, Dorigo O, Gjerset RA, Royston I, Sobol RE, and Fakhrai H. Comparison of gene therapy with interleukin-2 (IL-2) gene modified fibroblasts and tumor cells in the murine CT-26 model of colorectal carcinoma, J. Immunother., 17 (1995) 201–208.

    Article  CAS  Google Scholar 

  88. Santin AD, Ioli GR, Hiserodt JC, et al. Development and characterization of an IL-4-secreting human ovarian carcinoma cell line, Gynecol. Oncol., 58 (1995) 230–239.

    Article  PubMed  CAS  Google Scholar 

  89. Santin AD, Ioli GR, Hiserodt JC, et al. Development and in vitro characterization of a GM-CSF secreting human ovarian carcinoma tumor vaccine, Int. J. Gynecol. Cancer, 5 (1995) 401–410.

    Article  PubMed  Google Scholar 

  90. Sulitzenau D. Immunosuppressive factors in human cancer, Adv. Cancer Res., 60 (1993) 247–267.

    Article  Google Scholar 

  91. Hirte W, Clark DA, O’Connell G, Rusthoven J, and Mazurka J. Reversal of suppression of lymphokine-activated killer cells by transforming growth factor-beta in ovarian carcinoma ascitic fluid requires interleukin-2 combined with anti-CD3 antibody, Cell Immunol., 142 (1992) 207–216.

    Article  PubMed  CAS  Google Scholar 

  92. Hirte H and Clark DA. Generation of lymphokine-activated killer cells in human ovarian carcinoma ascitic fluid: identification of transforming growth factor-beta as a suppressive factor, Cancer Immunol. Immunother., 32 (1991) 296–302.

    Article  PubMed  CAS  Google Scholar 

  93. Dorigo O and Berek JS. Gene therapy for ovarian cancer: development of novel treatment strategies, Internat. J. Gynecol. Cancer, 7 (1997) 1–13.

    Article  CAS  Google Scholar 

  94. Vogelstein B and Kinzler KW. p53 function and dysfunction, Cell, 70 (1992) 523–526.

    Article  PubMed  CAS  Google Scholar 

  95. Hartmann LC, Podratz KC, Keeney GL, et al. Prognostic significance of p53 immunostaining in epithelial ovarian cancer, J. Clin. Oncol., 12 (1994) 64–69.

    PubMed  CAS  Google Scholar 

  96. Kupryjanczyk J, Thor AD, Beauchamp R, et al. p53 gene mutations and protein accumulation in human ovarian cancer, Proc. Natl. Acad. Sci. USA, 90 (1993) 4961–4965.

    Article  PubMed  CAS  Google Scholar 

  97. Runnebaum IB, Tong XW, Moebus V, et al. Multiplex PCR screening detects small p53 deletions and insertions in human ovarian cancer cell lines, Hum. Genet., 93 (1994) 620–624.

    Article  PubMed  CAS  Google Scholar 

  98. Berchuck A, Kohler MF, Marks JR, et al. p53 tumor suppressor gene frequently is altered in gynecologic cancers, Am. J. Obstet. Gynecol., 170 (1994) 246–252.

    PubMed  CAS  Google Scholar 

  99. Santoso JT, Tang DC, Lane SB, et al. Adenovirus-based p53 gene therapy in ovarian cancer, Gynecol. Oncol., 59 (1995) 171–178.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. John C. Elkas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Oliver Dorigo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jonathan S. Berek
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Cleveland Clinic Taussig Cancer Center, Department of Hematology/Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH, USA

    Maurie Markman MD (Director, Chairman) (Director, Chairman)

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer Science+Business Media New York

About this chapter

Cite this chapter

Elkas, J.C., Dorigo, O., Berek, J.S. (2000). Intraperitoneal Biologic Therapy for Ovarian Cancer. In: Markman, M. (eds) Regional Chemotherapy. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-219-7_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-219-7_12

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4684-9697-0

  • Online ISBN: 978-1-59259-219-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation